Hopstem Biotechnology
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3903 Bellaire Blvd, Houston, Texas, 7702...Phone Number
(215) 805-7423Website
www.hopstem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Hopstem Biotechnology
Hopstem Biotechnology, based in Houston, Texas, is an iPSC cell therapy company that created a neural differentiation platform and patented iPSC reprogramming method and high standard GMP manufactory and quality system.Explore more
Hopstem Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hopstem Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Hopstem Biotechnology recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hopstem Biotechnology
Funding: Get notified immidiatlly once Hopstem Biotechnology has new funding data
Product Launch: Get notified when Hopstem Biotechnology launches new products
Check out if Hopstem Biotechnology is spiking on competitors!
Hopstem Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Hopstem Biotechnology had a recent Job posting/layoffs
Check if Hopstem Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Hopstem Biotechnology
Compare insights from companies similar to Hopstem Biotechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hopstem Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hopstem Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hopstem Biotechnology.
Hopstem Biotechnology financials insights
Gather financial insights about Hopstem Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Seed
$1.8M
2021
Series A
$114.5M
Series B
$40M
Hopstem Biotechnology Tech Stack
A closer look at the technologies used by Hopstem Biotechnology
See more technologies
Hopstem Biotechnology News & Media
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
HOUSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track designations for hNPC01, an allogeneic induced pluripotent stem cell (iPSC)-derived forebrain neural progenitor cell therapy, for the treatment of chronic motor dysfunction due to Hemorrhagic Stroke (ICH) and Traumatic Brain Injury (TBI).Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its proprietary human forebrain neural progenitor cell injection, hNPC01. The candidate has displayed potential for treating persistent motor dysfunction due to basal ganglia ischemic stroke in phase I clinical study[1].FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging StudyHOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients
CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 /PRNewswire/ -- After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hopstem Biotechnology
Sign Up For FreeTo access detailed company insights
Hopstem Biotechnology, based in Houston, Texas, is an iPSC cell therapy company that created a neural differentiation platform and patented iPSC reprogramming method and high standard GMP manufactory and quality system.... Read More
